Molecular Partners Says $69 Million Can Fund Operations Into Late 2027
Photo: TokenPost
Molecular Partners AG had $69 million in cash and cash equivalents on Sept. 30, 2026, and said that balance would support operations into late 2027. The company plans to reduce its workforce by up to 55 positions, or about 44%. It expects to complete the changes by the second quarter of 2027. Dosing for MP0712 continues in Phase 1/2a. Safety data are expected in December 2026, with efficacy data due in 2027. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
